Cargando…

Ustekinumab in ulcerative colitis‐ insights from the real‐world data

Detalles Bibliográficos
Autores principales:	Veisman, Ido, Kopylov, Uri
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Inflammatory Bowel Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486495/ https://www.ncbi.nlm.nih.gov/pubmed/35841129 http://dx.doi.org/10.1002/ueg2.12278

Ejemplares similares

Ustekinumab treatment in ulcerative colitis: Real‐world data from the Swedish inflammatory bowel disease quality register
por: Thunberg, Joel, et al.
Publicado: (2022)

Real‐world use of endoscopic and histological indices in ulcerative colitis: Results of a global survey
por: Nardone, Olga Maria, et al.
Publicado: (2023)

High prevalence of ulcerative appendicitis in patients with ulcerative colitis
por: Heuthorst, Lianne, et al.
Publicado: (2021)

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)
por: Travis, Simon P L, et al.
Publicado: (2011)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis)
por: Probert, Christopher SJ, et al.
Publicado: (2018)

Menetrier’s disease exacerbating ulcerative colitis and relieved by gastrectomy
por: Kayes, Tahrima, et al.
Publicado: (2021)

Treatment-refractory ulcerative colitis responsive to indigo naturalis
por: Saiki, Julie P, et al.
Publicado: (2021)

Disease clearance in ulcerative colitis: Is the ultimate therapeutic target?
por: D’Amico, Ferdinando, et al.
Publicado: (2023)

Tacrolimus or infliximab for severe ulcerative colitis: short-term and long-term data from a retrospective observational study
por: Minami, Naoki, et al.
Publicado: (2015)

Mild to moderate ulcerative colitis: Call me by my name
por: Rodríguez‐Lago, Iago, et al.
Publicado: (2022)

Andrographis paniculata Extract (HMPL-004) for Active Ulcerative Colitis
por: Sandborn, William J, et al.
Publicado: (2013)

Living with Ulcerative Colitis Study (LUCY) in England: a retrospective study evaluating healthcare resource utilisation and direct healthcare costs of postoperative care in ulcerative colitis
por: Brookes, Matthew J, et al.
Publicado: (2020)

Ambulatory care management of 69 patients with acute severe ulcerative colitis in comparison to 695 inpatients: insights from a multicentre UK cohort study
por: Sebastian, Shaji, et al.
Publicado: (2022)

Inflammation decreases keratin level in ulcerative colitis; inadequate restoration associates with increased risk of colitis-associated cancer
por: Corfe, Bernard M, et al.
Publicado: (2015)

Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3
por: Colombel, Jean-Frederic, et al.
Publicado: (2014)

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
por: Rosario, M., et al.
Publicado: (2015)

Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease
por: Buisson, Anthony, et al.
Publicado: (2021)

Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis
por: Johansson, Malin E V, et al.
Publicado: (2014)

Bacterial O-GlcNAcase genes abundance decreases in ulcerative colitis patients and its administration ameliorates colitis in mice
por: He, Xiaolong, et al.
Publicado: (2021)

Acute appendicitis and ulcerative colitis: a population-based sibling comparison study
por: Garcia-Argibay, Miguel, et al.
Publicado: (2022)

Ulcerative colitis increases risk of hypertension in a UK biobank cohort study
por: He, Jinshen, et al.
Publicado: (2022)

Structural weakening of the colonic mucus barrier is an early event in ulcerative colitis pathogenesis
por: van der Post, Sjoerd, et al.
Publicado: (2019)

Two‐year effectiveness and safety of golimumab in ulcerative colitis: An IG‐IBD study
por: Pugliese, Daniela, et al.
Publicado: (2021)

Mesalazine granules promote disease clearance in patients with mild‐to‐moderate ulcerative colitis
por: Kruis, Wolfgang, et al.
Publicado: (2023)

Colectomy in patients with ulcerative colitis is not associated to future diagnosis of primary sclerosing cholangitis
por: Lundberg Båve, Aiva, et al.
Publicado: (2023)

The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies
por: Narula, Neeraj, et al.
Publicado: (2021)

Intestinal ultrasound for monitoring therapeutic response in patients with ulcerative colitis: results from the TRUST&UC study
por: Maaser, Christian, et al.
Publicado: (2020)

Review article: Updated management of acute severe ulcerative colitis: From steroids to novel medical strategies
por: Calméjane, Louis, et al.
Publicado: (2023)

Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis
por: Louis, Edouard, et al.
Publicado: (2022)

LIAISON(®) Calprotectin for the prediction of relapse in quiescent ulcerative colitis: The EuReCa study
por: Fiorino, Gionata, et al.
Publicado: (2022)

Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review
por: Caron, Bénédicte, et al.
Publicado: (2022)

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
por: Kamm, M A, et al.
Publicado: (2008)

Forty-Year Analysis of Colonoscopic Surveillance Program for Neoplasia in Ulcerative Colitis: An Updated Overview
por: Choi, Chang-Ho Ryan, et al.
Publicado: (2015)

Composite outcomes in observational studies of ulcerative colitis: A systematic review and meta‐analysis
por: Magro, Fernando, et al.
Publicado: (2021)

Milan ultrasound criteria are accurate in assessing disease activity in ulcerative colitis: external validation
por: Allocca, Mariangela, et al.
Publicado: (2021)

Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis
por: Voskens, Caroline, et al.
Publicado: (2023)

Reporting of endoscopy and histology of ulcerative colitis in routine clinical practice: How far we are!
por: Magro, Fernando, et al.
Publicado: (2023)

Dose escalation randomised study of efmarodocokin alfa in healthy volunteers and patients with ulcerative colitis
por: Wagner, Frank, et al.
Publicado: (2023)

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study
por: Travis, Simon P L, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ui155lqt9e0b5e1rrg9d7r5ve9